Holen Sie sich die Stockscreener-App
4.295
6.84%
0.275
Schlusskurs vom Vortag:
$4.02
Offen:
$4.12
24-Stunden-Volumen:
57,959
Relative Volume:
0.10
Marktkapitalisierung:
$153.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-42.05M
KGV:
-1.523
EPS:
-2.82
Netto-Cashflow:
$-35.26M
1W Leistung:
+6.84%
1M Leistung:
+3.25%
6M Leistung:
+128.46%
1J Leistung:
+20.31%
1-Tages-Spanne:
$4.1011
$4.30
1-Wochen-Bereich:
$3.65
$4.30
52-Wochen-Spanne:
$1.595
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
Firmenname
Protara Therapeutics Inc
Sektor
Branche
Telefon
646-844-0337
Adresse
345 PARK AVENUE SOUTH, NEW YORK, NY
Vergleichen Sie TARA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
4.30 | 153.14M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
510.04 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
670.18 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
602.20 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.01 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.60 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-07-10 | Fortgesetzt | Guggenheim | Buy |
| 2021-06-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-17 | Eingeleitet | Oppenheimer | Outperform |
| 2020-10-19 | Eingeleitet | Cowen | Outperform |
| 2020-07-29 | Eingeleitet | Guggenheim | Buy |
Protara Therapeutics Inc Aktie (TARA) Neueste Nachrichten
Cantor Fitzgerald Initiates Coverage on Protara Therapeutics With Overweight Rating -March 14, 2025 at 07:33 am EDT - Marketscreener.com
Analysts Set Expectations for TARA Q1 Earnings - Defense World
Protara Therapeutics (NASDAQ:TARA) Coverage Initiated by Analysts at Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Protara Therapeutics (TARA) with Outperform Recommendation - Nasdaq
HC Wainwright Issues Positive Forecast for TARA Earnings - Defense World
What is HC Wainwright’s Forecast for TARA FY2029 Earnings? - Defense World
Protara Therapeutics’ (TARA) Buy Rating Reiterated at HC Wainwright - Defense World
Protara Therapeutics’ TARA-002 Shows Promising Efficacy and Safety in HR-NMIBC, Earning Buy Rating - TipRanks
H.C. Wainwright maintains Buy rating on Protara stock, $23 target By Investing.com - Investing.com UK
Protara Therapeutics (NASDAQ:TARA) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Protara Therapeutics: Q4 Earnings Snapshot - Midland Daily News
Protara Therapeutics Reports Progress and Financial Results - TipRanks
Protara Therapeutics shares rise on narrower Q4 loss By Investing.com - Investing.com South Africa
Protara Therapeutics shares rise on narrower Q4 loss - Investing.com
Protara Therapeutics reports Q4 EPS (48c) vs (90c) last year - TipRanks
Protara Therapeutics: Q4 Earnings Snapshot -March 05, 2025 at 08:21 am EST - Marketscreener.com
Protara Therapeutics, Inc. SEC 10-K Report - TradingView
Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - TradingView
Can Protara's 72% Response Rate in Bladder Cancer Trial Transform Treatment Landscape? - StockTitan
Protara Therapeutics (TARA) Projected to Post Quarterly Earnings on Wednesday - Defense World
Protara Therapeutics Stock Doubles On Promising Bladder Cancer Trial Data: Retail Buzz Spikes - MSN
Protara Therapeutics (NASDAQ:TARA) Stock Price Down 4%Here's What Happened - MarketBeat
Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
Rare Disease Biotech Protara Sets Investor Presentation: What's Next for TARA Pipeline? - StockTitan
Protara Therapeutics (NASDAQ:TARA) Stock Price Down 4% – Should You Sell? - Defense World
Certain Pre-Funded warrants of Protara Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2025. - Marketscreener.com
Certain Common Warrants of Protara Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2025. - Marketscreener.com
Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Reviewing Protara Therapeutics (NASDAQ:TARA) and Palisade Bio (NASDAQ:PALI) - Defense World
Exclusive Healthcare Insights: Protara Therapeutics Takes Center Stage at Major Oppenheimer Conference - StockTitan
Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Significant Drop in Short Interest - MarketBeat
Protara Therapeutics (NASDAQ:TARA) vs. Cardiff Oncology (NASDAQ:CRDF) Head-To-Head Review - Defense World
Geode Capital Management LLC Purchases 29,514 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Highlights Recent Updates and Anticipated 2025 Milestones - The Manila Times
Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Increase in Short Interest - MarketBeat
XTX Topco Ltd Buys New Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Velan Capital Investment Management LP Increases Stake in Protara Therapeutics Inc - GuruFocus.com
Flatiron-based drug company raises $100M for cancer treatment - Crain's New York Business
Protara Therapeutics: Rising From The Ashes (NASDAQ:TARA) - Seeking Alpha
Protara Therapeutics Raises $100M in Stock Offering - TipRanks
Protara Announces Closing of $100 Million Public Offering - GlobeNewswire
SEC Form 424B5 filed by Protara Therapeutics Inc. - Quantisnow
Protara Therapeutics Secures Massive $100M Public Offering to Advance TARA-002 Development - StockTitan
Protara Therapeutics: Carving New Roads In Bladder Cancer (TARA) - Seeking Alpha
Finanzdaten der Protara Therapeutics Inc-Aktie (TARA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Protara Therapeutics Inc-Aktie (TARA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
Sep 11 '24 |
Sale |
1.71 |
32,600 |
55,880 |
51,500 |
| Opaleye Management Inc. | 10% Owner |
Sep 09 '24 |
Sale |
1.89 |
36,492 |
69,141 |
54,600 |
| Opaleye Management Inc. | 10% Owner |
Sep 10 '24 |
Sale |
1.77 |
25,500 |
45,110 |
53,100 |
| Opaleye Management Inc. | 10% Owner |
Jul 16 '24 |
Sale |
2.44 |
11,396 |
27,828 |
56,500 |
| Opaleye Management Inc. | 10% Owner |
Jul 11 '24 |
Sale |
2.40 |
47,993 |
115,346 |
60,000 |
| Opaleye Management Inc. | 10% Owner |
Jul 10 '24 |
Sale |
2.31 |
18,061 |
41,685 |
75,000 |
| Opaleye Management Inc. | 10% Owner |
Jul 09 '24 |
Sale |
2.21 |
8,497 |
18,811 |
80,000 |
| Opaleye Management Inc. | 10% Owner |
Jul 01 '24 |
Sale |
2.12 |
8,288 |
17,598 |
87,500 |
| Opaleye Management Inc. | 10% Owner |
Jun 27 '24 |
Sale |
2.26 |
46,574 |
105,169 |
90,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 28 '24 |
Sale |
2.07 |
17,994 |
37,334 |
85,000 |
1.28%
0.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):